INTRODUCTION
Leukemia cutis (LC) is the term used for cutaneous manifestations of leukemia. 1 The clinical and morphological findings have a wide range of cutaneous manifestations and may present with nodular lesions and plaques. Rare manifestations include erythematous macules, blisters and ulcers which can each occur alone or in combination. 2 The lesions may be localized or disseminated and can occur on any site of the skin. 2 Histologic features of LC vary with the type of leukemia. The infiltrate of neoplastic leukocytes may be perivascular, nodular and diffuse, or densely surrounding the eccrine glands. The diagnosis of LC is verified by skin biopsy and immunophenotyping. The purpose of this study was to study the clinical, histopathological and immunohistochemical features of 10 patients with myeloid leukemia cutis (MLC). 
METHODS

Case selection
Clinical data
RESULTS
General data
The ten cases included one patient with AML-M1 (acute myelocytic leukemia), one patient with AML-M2, three patients with AML-M3, one patient with AML-M4, one patient with chronic myelomonocytic leukemia (CMML) and three patients with granulocytic sarcoma (GS). The male-female ratio was 3:2. Mean age was 49.3 years at the time of diagnosis. One patient developed skin lesions 8 months earlier than the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously (Table 1) . (Table 1) . (Table 3) .
Clinical appearance and distribution
Histopathological, immunohistochemical and molecular features
DISCUSSION
MLC often presents as generalized or localized nodules or
masses with characteristic pathological and histochemical manifestations. Particularly, the presence of skin infiltration is often associated with a poor prognosis and short survival time.
Skin manifestations
Among the 10 patients in this study, five presented with generalized erythematous infiltrated papules, maculopapules or nodules, and five presented with localized masses. Kaddu et al 3 reported that MLC presented as solitary or multiple reddish to violaceous papules, plaques, and nodules (17 lesions), or as a generalized erythematous maculopapular eruption (9 lesions). In this study, nodules, papules and masses are commonly seen in 10 patients. Nodules are most frequently seen in AML, whereas papules were the most common lesion in CML. In Kang's study, the most commonly clinically observed skin lesions were nodules, papules, and plaques, in decreasing order. 4 Specifically, case 8 and 10 in our study only presented with oral lesions, which occurred after the onset of leukemia. Oral manifestations occur frequently in leukemia patients and may present as initial evidence of the disease or its relapse. These oral lesions may either be the result of direct infiltration of leukemia cells (primary) or secondary to underlying thrombocytopenia, neutropenia, or impaired granulocyte function. The distribution of skin lesions was similar in most kinds of leukemia. In this study, the face, extremities and trunk were the most frequent locations of MLC. AML and CMML lesions were often located on extremities and trunk, while GS lesions did not. Most lesions were disseminated, while four cases were localized. Watson et al. 5 found that the distribution of skin lesions was found to be similar in patients with AML, CML and CLL (chronic lymphocytic leukemia), there was no apparent predilection for the sites of involvement. In a study of 75 patients with LC, they also described similar distribution features. 4 In this study, one patient developed skin lesions A B and molecular genetic studies (e.g., bone marrow biopsy) are needed. 7 The gene mutation of FLT3 and NPM1 in patients with acute myeloid leukemia is common. These two mutations are frequently AML, acute myelocytic leukemia; CMML, chronic myelomonocytic leukemia; GS, granulocytic sarcoma; MPO, Myeloperoxidase. 8, 9 At present, information about these mutations are assuming as much significance as cytogenetics in decisions about therapy. 10 In this study, positive FLT3-ITD and NPM1 were only seen in case 1.
Therefore, it is difficult for us to analyze the correlation between the gene results and the prognosis of the patients.
Prognosis
Skin lesion is generally indicative of a poor prognosis, and is associated with transformation into a blastic phase and suggests disease progression. 7 Kaddu et al. 3 reported that all patients with CML and AML with adequate follow-up died within 24 months after the onset of skin lesions (mean survival, AML: 7.6 months; CML:
9.4 months). Kang et al. 11 reported that the prognosis of LC was poor within one year. In Watson's study, the time from the appearance of LC to death ranged from three months (CML) to 39 months (CLL). In this study, six patients with AML and one patient with CMML died within two months to one year after the onset of skin lesions. 5 The average interval between the onset of MLC and death was 5.6 months, and the result in Kang's study was 8.3 months.
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CONCLUSION
The presence of skin infiltration is often associated with a poor prognosis and short survival time. At present, the diagnosis of LC is often made in retrospect once leukemia becomes present clinically. 12 Therefore, it is imperative that clinicians be familiar with features of cutaneous lesions that may indicate an underlying malignancy. 13 A skin biopsy can be the first indication of the presence of leukemia cutis in the patients with systemic leukemia. 14, 15 This was a retrospective and small sample study, which is its limitation. q 
